09:25:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo.


2021-11-17 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-07-28 Extra Bolagsstämma 2021
2021-05-21 Ordinarie utdelning PHO 0.00 NOK
2021-05-20 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-03 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning PHO 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-07 Kvartalsrapport 2019-Q2
2019-06-19 Extra Bolagsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning PHO 0.00 NOK
2019-05-09 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-23 Kvartalsrapport 2018-Q1
2018-05-11 Ordinarie utdelning PHO 0.00 NOK
2018-05-09 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-04-28 Ordinarie utdelning PHO 0.00 NOK
2017-04-27 Årsstämma 2017
2017-02-15 Bokslutskommuniké 2016
2016-11-15 Kvartalsrapport 2016-Q3
2016-08-23 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-29 Ordinarie utdelning PHO 0.00 NOK
2016-04-28 Årsstämma 2016
2016-02-11 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-02 Ordinarie utdelning PHO 0.00 NOK
2015-04-30 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning PHO 0.00 NOK
2014-05-27 Årsstämma 2014
2014-05-07 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning
2013-05-22 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-05-10 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-27 Årsstämma 2011
2011-04-27 Kvartalsrapport 2011-Q1
2011-02-17 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-19 Bokslutskommuniké 2009
2009-11-26 Bonusutdelning
2021-05-19 07:00:12
Oslo, Norway, 19 May 2021: Photocure ASA (OSE:PHO), the Bladder Cancer Company,
today reported Hexvix[®]/Cysview[®] revenues of NOK 81.6 million in the first
quarter of 2021 (Q1 2020: NOK 54.4 million), and EBITDA of NOK 18.1 million (NOK
-4.8 million), following the continued successful launch in markets previously
operated by Ipsen Pharma SAS. The third Covid-19 wave impacted operations in the
quarter, but a strong March performance indicates the environment is improving.

"For the first quarter of 2021, Photocure delivered a 50% YoY increase in
Hexvix/Cysview sales, unit growth in our U.S. segment, and positive EBITDA
driven by the added revenue in Europe, cost containment, and the payment from
Asieris to license Hexvix in China and Taiwan. I am pleased with this
performance, particularly given the negative impact from the third wave of Covid
-19 in January and February of this year, foreign currency headwinds during the
quarter, and the difficult comparison to the same period last year when pandemic
lockdowns and limited access to care did not occur until mid-March. While access
is still closed or significantly restricted in many areas, strong performance in
the last month of the quarter in both our U.S. and European segments suggests
that the environment is improving," says Daniel Schneider, President & Chief
Executive Officer of Photocure.

Photocure reported total group revenues of NOK 88.2 million in the first quarter
of 2021 (NOK 55.0 million), with an EBITDA* before restructuring of NOK 18.1
million (NOK -4.8 million) including signing fees from Asieris totaling NOK 6.4
million for the commercialization of Hexvix in Mainland China and Taiwan.
Hexvix/Cysview revenues were NOK 81.6 million (NOK 54.4 million) following the
successful transition of the Ipsen territories, while unit growth in the U.S.
increased 4% despite the limited access to hospitals and physicians due to Covid
-19. EBIT grew to NOK 12.3 million (-10.5 million) and the cash balance at the
end of the first quarter 2021 was NOK 329.5 million (127.6 million).

The installed base of blue light cystoscopes in the U.S. was 280 at the end of
the first quarter, an increase of 42 units, or 18%, compared to the same period
in 2020. Blue Light Cystoscopy (BLC[®]) in the surveillance setting is a key
priority for Photocure in the U.S. market. By the end of the first quarter, a
total base of 41 flexible cystoscopes had been installed giving more patients
access to the procedure with less constraints.

"Despite the ongoing commercial challenges, we continued to advance several
initiatives to grow the installed base of Blue Light Cystoscope towers and to
prepare for increasing procedure volumes when full access to care reopens. In
the U.S., we installed 12 new towers during the quarter including 3 flexible
Blue Light Cystoscope units. Our growing pipeline suggests the potential for
acceleration of Blue Light Cystoscope installations during the remainder of the
year, and we believe that the benefits of Blue Light Cystoscopy with
Hexvix/Cysview offering superior detection and management of bladder cancer will
continue to be adopted and become the standard of care, " Schneider adds.

The ongoing Covid-19 pandemic adds continued uncertainty to Photocure's near
-term business forecast, but the Company believes that in places where
procedures have been postponed due to the fear of exposure to Covid-19, the
number of procedures is expected to rebound back to pre-Covid-19 growth rates in
the U.S. and positive growth in the Company's newly acquired European markets.

"Our contracting strategies in the U.S. are also gaining traction and expected
to lead to new account growth and higher penetration into our existing
institutional customers and physician clinics. In Europe, where we are
introducing Photocure as the new sponsor of Hexvix, we have had strong buy-in
from leading key opinion leaders in target countries. Despite limited access to
our new customers, we are seeing early indications of a turn-around in our key
growth markets such as the UK, France, and Italy. As access improves, we will
continue to staff our European operations and invest in order to generate
additional growth in the region. Our performance in dealing with the ongoing
business volatility, including the sales rebound that we saw in March, gives me
confidence that we are taking the right steps to return to strong growth and to
execute on our strategy to become a leader in the diagnosis and treatment of
bladder cancer patients around the world" Schneider concludes.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
first quarter 2021 financial report on page 23.

Photocure will present its first quarter 2021 report on Wednesday 19 May 2021 at
14:00 CET. The investor presentation will be streamed live and be hosted by
Daniel Schneider, CEO and Erik Dahl, CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20210519_6/. The
presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 19 May 2021 at 07:00 CET.